Major Depressive Disorder - Epidemiology Forecast to 2029

Major Depressive Disorder - Epidemiology Forecast to 2029

Summary

Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as a mood disorder that may lead to a variety of emotional and physical problems (Mayo Clinic, 2018). MDD is characterized by persistent feelings of sadness, anger, irritability or frustration, loss of interest in activities, and overeating or loss of appetite that can last from days to months, which alternates with episodes of wellness (MedlinePlus, 2020). MDD is a highly debilitating condition associated with substantial morbidity, and an enormous social and economic burden (Kessler and Bromet, 2013). The condition affects the thoughts, feelings, behavior, and physical health of an individual, leading to a range of psychological, physical, and social problems. Little is known about the etiology of MDD; however, research suggests that there may be combinations of genetic, biological, environmental, and psychological factors that potentially increase the risk of MDD (Kessler and Bromet, 2013; Mayo Clinic, 2018; National Institute of Mental Health, 2018; MedlinePlus, 2020).

In the 8MM, GlobalData epidemiologists forecast that the 12-month total prevalent cases of MDD will increase from 53,373,325 12-month total prevalent cases in 2019 to 55,363,640 12-month total prevalent cases in 2029, at an Annual Growth Rate (AGR) of 0.37%. The US will have the highest number of 12-month total prevalent cases of MDD among the 8MM throughout the forecast period, while Canada will have the lowest number of 12-month total prevalent cases of MDD.

Scope

- Major depressive disorder (MDD) Epidemiology Report and Model provide an overview of the risk factors and the global and historical trends for MDD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
- The report includes a 10-year epidemiological forecast for the 12-month total prevalent cases of MDD based on the American Psychiatric Associations (APA) Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. The 12-month total prevalent cases of MDD (including diagnosed and undiagnosed) are further segmented by age, sex, and severity (mild, moderate, and severe).
- This epidemiology forecast for MDD is supported by historical data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast total prevalent cases of MDD across these markets.
- The MDD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
- The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The MDD Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MDD market.
- Quantify patient populations in the global MDD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for MDD therapeutics in each of the markets covered.
- Understand magnitude of MDD by severity.
1
1.1 List of Tables
1.2 List of Figures
2 Major Depressive Disorder: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalence of MDD
3.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalence of MDD by Severity
3.5 Epidemiological Forecast for MDD (2019-2029)
3.5.1 12-Month Total Prevalent Cases of MDD
3.5.2 Age-Specific 12-Month Total Prevalence of MDD
3.5.3 Sex-Specific 12-Month Prevalent Cases of MDD
3.5.4 12-Month Total Prevalent Cases of MDD by Severity for Ages <18 Years
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Coronavirus Disease 2019 (COVID-19) Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

List Of Tables


Table 1: Summary of Newly Added Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for MDD

List Of Figures


Figure 1: 8MM, 12-Month Total Prevalent Cases of MDD, Both Sexes, N, Ages 18 Years, 2019 and 2029
Figure 2: 8MM, 12-Month Total Prevalence of MDD (%), Men and Women, Ages 18 Years, 2019
Figure 3: 8MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of MDD
Figure 4: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD, by Severity
Figure 5: 8MM, 12-Month Total Prevalent Cases of MDD, N, Both Sexes, Ages 18 Years, 2019
Figure 6: 8MM, 12-Month Total Prevalent Cases of MDD by Age, N, Both Sexes, 2019
Figure 7: 8MM, 12-Month Total Prevalent Cases of MDD by Sex, N, Ages 18 Years, 2019
Figure 8: 8MM, Total Prevalent Cases of MDD by Severity, N, Ages 18 Years, 2019

Major Prion Protein (ASCR or PrP27-30 or PrP33-35C or CD230 or PRNP) - Drugs in Development, 2021

Major Prion Protein (ASCR or PrP27-30 or PrP33-35C or CD230 or PRNP) - Drugs in Development, 2021Major Prion Protein (ASCR or PrP27-30 or PrP33-35C or CD230 or PRNP) - Drugs

USD 3000 View Report

Cruzipain (Major Cysteine Proteinase or Cruzain or EC 3.4.22.51) - Drugs in Development, 2021

Cruzipain (Major Cysteine Proteinase or Cruzain or EC 3.4.22.51) - Drugs in Development, 2021Cruzipain (Major Cysteine Proteinase or Cruzain or EC 3.4.22.51) - Drugs in Development, 2021 provides in depth

USD 3000 View Report

Major Depressive Disorder (Central Nervous System) - Drugs in Development, 2021

Major Depressive Disorder (Central Nervous System) - Drugs in Development, 2021Major Depressive Disorder (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Major Depressive Disorder pipeline

USD 2000 View Report

Major Depressive Disorder Global Clinical Trials Review, H2, 2020

Major Depressive Disorder Global Clinical Trials Review, H2, 2020clinical trial report, Major Depressive Disorder Global Clinical Trials Review, H2, 2020 provides an overview of Major Depressive Disorder Clinical trials scenario.

USD 2500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available